SavedAdd your journal

Journals / Turkish Journal of Medical Sciences / 2005 / Cilt: 35 - Sayı: 4

Juvenile Dermatomyositis Resistant to Steroids

Muzaffer POLAT
İpek AKIL
Tarkan İKİZOLU
Selim SERTER
Mine ÖZKOL
Pages
261–265
Publication Date
2005-04-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Key Words: Juvenile dermatomyositis, treatment, resistant to steroids

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Key Words: Juvenile dermatomyositis, treatment, resistant to steroids
📊
Key Findings & Data:Key Words: Juvenile dermatomyositis, treatment, resistant to steroids
💡
Conclusion & Impact:Key Words: Juvenile dermatomyositis, treatment, resistant to steroids
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Turk J Med Sci 2005 · 35(4): 261-265. Full text: pdf Other articles published in the same issue: Turk J Med Sci · vol.35

Abstract

Key Words: Juvenile dermatomyositis, treatment, resistant to steroids

Özet

Key Words: Juvenile dermatomyositis, treatment, resistant to steroids

🔖

Cite This Article

POLAT, M., AKIL, İ., İKİZOLU, T., SERTER, S., ÖZKOL, M. (2005). Juvenile Dermatomyositis Resistant to Steroids. Turkish Journal of Medical Sciences, Cilt: 35 - Sayı: 4, 261–265. https://ajindex.com/articles/723702

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Rider LG, Miller FW. Idiopathic inflammatory muscle disease: clinical aspects. Baillieres Best Pract Res Clin Rheumatol 14: 37- 54, 2000
  2. Ramanan AV, Feldman BM. Clinical outcomes in juvenile dermatomyositis. Curr Opin Rheumatol 14: 658-62, 2002
  3. Callen JP. Dermatomyositis: diagnosis, evaluation and management. Minerva Med 93: 157-67, 2002
  4. Fisler RE, Liang MG, Fuhlbrigge RC et al. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 47: 505- 11, 2002
  5. Wedderburn LR, Li CKC. Paediatric idiopathic inflammatory muscle disease. Best Pract Res Clin Rheumatol 18: 345–8, 2004
  6. Pachman LM, Hayford JR, Chung A et al. Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheumatol 25: 198–204, 1998
  7. Pachman LM. Juvenile dermatomyositis. Pathophysiology and disease expression. Pediatr Clin North Am 42: 1071-98, 1995
  8. Chandrasekaran AN, Rajendran CP, Thenmozhivalli PR et al. Spectrum of clinical and immunological features of systemic rheumatic diseases in a referral hospital in south India: juvenile dermatomyositis/polymyositis. J Indian Rheum Assoc 3: 141-3, 1995
  9. Brottier L, Coste P, Combe C et al. Cardiac complications of dermatopolymyositis. Arch Mal Coeur Vaiss 80: 1133–8, 1987
  10. Cloatre G, Sane M, Wade B et al. Cardiac manifestations of polymyositis. Apropos of 2 Senegalese cases. Rev Med Interne 19: 265-70, 1998
  11. Soylu A, Kavukcu S, Turkmen M et al. Dermatomyositis with membranous nephropathy.Turk J Pediatr 43: 143-145, 2001
  12. Pasquali JL, Meyer P, Christmann D et al. Renal manifestations in dermatomyositis and polymyositis. Ann Med Interne 138: 109- 113, 1987
  13. Kasteler JS, Callen JP. Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis. Am Acad Dermatol 36: 67-71, 1997
  14. Zipitis CS, Baildam EM, Ramanan AV. Treatment approaches to juvenile dermatomyositis. Expert Opin Pharmacother 5: 1509- 15, 2004
  15. Al-Mayouf S, Al-Mazyed A, Bahabri S. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate. Clin Rheumatol 19: 138- 141, 2000.